Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Song, YQ; Zhou, KS; Zou, DH; Zhou, JF; Hu, JD; Yang, HY; Zhang, HL; Ji, J; Xu, W; Jin, J; Lv, FF; Feng, R; Gao, SJ; Guo, HY; Zhou, L; Huang, J; Novotny, W; Kim, P; Yu, YL; Wu, BH; Zhu, J

Zhu, J (通讯作者)，Peking Univ Canc Hosp & Inst, 52 Fucheng Rd, Beijing 100142, Peoples R China.

BLOOD, 2022; 139 (21): 3148

Abstract

Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly se......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索